Director · Iambic Therapeutics, Inc. · Iambic Therapeutics, Inc. — Series B Convertible Preferred Stock
Side
C
Value
—
Shares
731.2K
Price
—
Executed
Oct 16, 2026
Disclosed
Oct 19, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Oct 16 executedOct 19, 2026 disclosed
IAM · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Derivative conversion — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Iambic Therapeutics, Inc. — Series B Convertible Preferred Stock
Ticker
IAM
Shares
731.2K
Price per share
$0
Execution date (reported)
Oct 16, 2026
Owned after transaction
0 shares
Days from execution to publication
3
What this establishes
Vogelstein R Jacob filed this Form 4 reporting a derivative conversion of IAM on Oct 16, 2026. It became public on Oct 19, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Vogelstein R Jacobcik:0002154030
Issuer
Iambic Therapeutics, Inc.cik:0001997038
Revision history · 0
No field has changed since this record was first ingested.
